<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30156427</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>29</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1744-8301</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Future oncology (London, England)</Title>                <ISOAbbreviation>Future Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Mammaprint™: a comprehensive review.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2018-0221</ELocationID>            <Abstract>                <AbstractText>The number of breast cancer (BC) cases is growing worldwide, being most frequently diagnosed in the early-setting. Mammaprint™ is a 70-gene-expression signature, originally designed for selecting early BC patients with low risk of developing metastasis, so that they could be spared adjuvant chemotherapy. Its use as a prognostic biomarker has been extensively validated, both retrospectively and prospectively. However, its value as a predictive tool and as a clinically useful tool remains controversial. This review will describe how the test works, its application in the clinic and its limitations. Cost-effectiveness studies will be summarized. Finally, we will provide a perspective on the use of Mammaprint in the near future, as a valuable tool for personalizing the treatment of early BC patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Brandão</LastName>                    <ForeName>Mariana</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institut Jules Bordet &amp; L'Université Libre de Bruxelles (U.L.B.), 121, 1000, Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pondé</LastName>                    <ForeName>Noam</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Institut Jules Bordet &amp; L'Université Libre de Bruxelles (U.L.B.), 121, 1000, Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Piccart-Gebhart</LastName>                    <ForeName>Martine</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institut Jules Bordet &amp; L'Université Libre de Bruxelles (U.L.B.), 121, 1000, Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Future Oncol</MedlineTA>            <NlmUniqueID>101256629</NlmUniqueID>            <ISSNLinking>1479-6694</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">adjuvant chemotherapy</Keyword>            <Keyword MajorTopicYN="N">breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">gene-expression signatures</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30156427</ArticleId>            <ArticleId IdType="doi">10.2217/fon-2018-0221</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>